67
Participants
Start Date
December 16, 2021
Primary Completion Date
August 28, 2024
Study Completion Date
August 28, 2024
RP-6306 (oral PKMYT1 inhibitor)
RP-6306 in combination with gemcitabine
# 1008, Columbia University, New York
# 1004, Memorial Sloan Kettering Cancer Institute, New York
# 1010, University of Pennsylvania, Philadelphia
# 1017, Mayo Clinic, Jacksonville
# 1022, Moffitt Cancer Center, Tampa
# 1023, START Midwest, Grand Rapids
# 1016, Mayo Clinic, Rochester
# 1018, Mayo Clinic, Phoenix
# 1019, UCLA, Westwood Cancer Center, Los Angeles
# 2001, Princess Margaret Cancer Centre, Toronto
# 3003, Sarah Cannon Research Institute, London
Lead Sponsor
Repare Therapeutics
INDUSTRY